Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors
Contineum Therapeutics, Inc. - Common stock (CTNM)
Company Research
Source: Business Wire
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Diego Miralles, M.D. as a member of its board of directors, effective March 14, 2025.“We are excited to welcome Diego to our board,” commented Eef Schimmelpennink, Contineum’s Chairperson. “He has successfully led the development of novel therapies throughout his distinguished career and has an extensive track record in both early stage research and all stages of clinical development. During his time at Janssen Research, Dr. Miralle
Read more
Impact Snapshot
Event Time:
CTNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTNM alerts
High impacting Contineum Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CTNM
News
- Contineum Therapeutics, Inc. (NASDAQ: CTNM) is now covered by analysts at Jones Trading. They set a "buy" rating and a $23.00 price target on the stock.MarketBeat
- Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS ForumBusiness Wire
- Contineum Therapeutics, Inc. (NASDAQ: CTNM) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $25.00 price target on the stock.MarketBeat
- Contineum Therapeutics, Inc. (NASDAQ: CTNM) had its price target lowered by analysts at Robert W. Baird from $32.00 to $16.00. They now have an "outperform" rating on the stock.MarketBeat
- Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones [Yahoo! Finance]Yahoo! Finance
CTNM
Earnings
- 3/6/25 - Miss
CTNM
Sec Filings
- 3/17/25 - Form 4
- 3/17/25 - Form 3
- 3/17/25 - Form 8-K
- CTNM's page on the SEC website